Page 92 - 2021_06-Haematologica-web

M.-E.M. Percival et al. Vienna, Austria; 2017.
12.Walter RB, Othus M, Orlowski KF, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for med- ically less fit adults with newly diagnosed acute myeloid leukemia or other high- grade myeloid neoplasm. Haematologica. 2018;103(3):e106-e109.
13. Halpern AB, Othus M, Gardner KM, et al. Mini- Vs. Regular-dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in medically less fit adults with newly-diagnosed acute myeloid leukemia (AML) and other high-grade myeloid neoplasms. Blood. 2019;134(Suppl 1):S1364.
14. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and
myelodysplasia. J Clin Oncol. 1995;13(11):
2827-2834.
15.Khan HM, Gardner KM, Shaw C, et al.
Need for routine examination of left ven- tricular ejection fraction in patients with AML. Leukemia. 2020;34(4):1169-1171.
16. Statler A, Radivoyevitch T, Siebenaller C, et al. The relationship between eligibility cri- teria and adverse events in randomized controlled trials of hematologic malignan- cies. Leukemia. 2017;31(8):1808-1815.
17. Buckley SA, Percival ME, Othus M, et al. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on ver- sus off study. Leuk Lymphoma. 2019;60 (4):1023-1029.
18. Ostgard LS, Norgaard M, Sengelov H, et al. Improved outcome in acute myeloid
leukemia patients enrolled in clinical trials: a national population-based cohort study of Danish intensive chemotherapy patients. Oncotarget. 2016;7(44):72044- 72056.
19. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual dis- ease and their prognostic impact on out- come in acute myeloid leukemia. J Clin Oncol. 2015;33(11):1258-1264.
20. Bhatt VR, Shostrom V, Giri S, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. Am J Hematol. 2017;92(8):764-771.
21. Montalban-Bravo G, Huang X, Naqvi K, et al. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syn- dromes not eligible for standard clinical tri- als. Leukemia. 2017;31(2):318-324.
2120
haematologica | 2021; 106(8)